GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 46,933 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,933 shares of the business’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61. Following the completion of the sale, the chief executive officer directly owned 91,514 shares of the company’s stock, valued at $5,780,939.38. The trade was a 33.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total transaction of $1,319,347.20.
• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The stock was sold at an average price of $78.61, for a total value of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total value of $155,382.00.

GeneDx Stock Up 0.2%

NASDAQ WGS traded up $0.13 on Thursday, hitting $65.65. 56,819 shares of the stock traded hands, compared to its average volume of 761,160. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average of $83.17 and a 200 day moving average of $115.33. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The company has a market capitalization of $1.92 billion, a P/E ratio of -87.74 and a beta of 2.17.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. As a group, analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. BTIG Research dropped their target price on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. Piper Sandler reaffirmed an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group raised their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Guggenheim decreased their target price on GeneDx from $170.00 to $100.00 and set a “buy” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $140.71.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently modified their holdings of WGS. Royal Bank of Canada increased its holdings in shares of GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after acquiring an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in GeneDx by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares during the last quarter. NewEdge Advisors LLC increased its stake in shares of GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after buying an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in shares of GeneDx during the second quarter valued at approximately $249,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.